On April 15, 2026, the Ministry of Ayush issued a directive that received almost no media coverage: ashwagandha leaves were strictly prohibited in all Ayush drugs and products across India.
The next day — April 16, 2026 — FSSAI extended the same ban to every food product, nutraceutical, and health supplement in the country.
The reason: 20% of commercial ashwagandha products tested contained leaf material that was never supposed to be there. The compound concentrated in those leaves — withaferin-A — has been linked to 35 documented cases of liver injury and 3 deaths.
India is the world’s largest producer of ashwagandha. Millions of Indians take it daily. And until April 2026, there was no regulation preventing manufacturers from substituting cheap leaf material for roots and selling it as “ashwagandha” without distinction.
That era is over. Here’s what changed, why it matters, and what you need to check on your supplement shelf right now.
What Exactly Was Banned
The FSSAI Order (April 16, 2026)
Under existing food safety regulations, FSSAI formally prohibited:
- Ashwagandha leaves in crude form
- Ashwagandha leaf extracts in any form
- Any ashwagandha leaf-derived material in food products, nutraceuticals, and health supplements
What remains legal: Only ashwagandha roots and root extracts are permitted under Schedule IV of the Food Safety and Standards regulations.
The Ministry of Ayush Order (April 15, 2026)
One day earlier, the Ministry of Ayush issued a parallel directive:
- Strictly prohibited ashwagandha leaves in all Ayush drugs and products
- Applies to Ayurvedic, Unani, Siddha, and Homeopathic preparations
- Covers manufacturing, sale, and distribution
New Labelling Requirement
Manufacturers must now disclose which plant part is used on product labels. Previously, a product could simply say “Ashwagandha 500mg” without specifying whether it contained root, leaf, stem, or whole plant material. This ambiguity is no longer permissible.
Non-compliance attracts action under the Food Safety and Standards Act, 2006 — penalties range from product seizure and fines to imprisonment for repeat or severe violations.
Why Leaves Were Banned: The Science
The ban wasn’t arbitrary. It was driven by three converging lines of evidence.
Evidence 1: Withaferin-A Toxicity
Ashwagandha contains dozens of withanolide compounds. The split between root and leaf isn’t just botanical trivia — it determines which compounds dominate:
| Compound | Root Concentration | Leaf Concentration | Effect |
|---|---|---|---|
| Withanolide-D | Higher | Lower | Neuroprotective, anti-inflammatory |
| Withaferin-A | Lower | Significantly higher | Anti-cancer (lab) but hepatotoxic (humans) |
| Triethylene glycol (TEG) | Minimal | Higher | Sleep-inducing |
| Total withanolides | 0.5–5% (standardised extracts) | Higher total, different composition | Mixed |
Withaferin-A is the problem compound. In laboratory studies, it shows anti-cancer and anti-tumour properties — which is why some researchers have studied it. But in real human consumption, it has been associated with:
- Liver toxicity — the primary safety concern driving the ban
- Gastrointestinal distress — nausea, vomiting, diarrhoea
- Potential neurotoxic effects — documented in animal studies at high doses
The danger is amplified by the 70-fold variation in withaferin-A content across commercial products. A consumer taking one brand might get a safe dose; switching to another brand could deliver 70x more withaferin-A — with no way to know from the label.
Evidence 2: 35 Liver Injury Case Reports
Since 2017, medical literature has documented 35 cases of ashwagandha-associated liver injury. An Indian case series of 8 patients provides the most detailed data:
- Onset: As early as 14 days after starting ashwagandha. Median 45 days.
- Presentation: Jaundice (87.5%), pruritus (62.5%), lethargy
- Lab values: Total bilirubin 13.8 mg/dL, AST 171 U/L, ALT 173 U/L
- Patterns: Cholestatic (4), hepatocellular (3), mixed (1)
- Deaths: 3 out of 8 (37.5%) — all had pre-existing chronic liver disease
- Recovery (survivors): 1–4 months after discontinuation
Not all 35 cases can be definitively attributed to leaf contamination. But the correlation between higher withaferin-A exposure (leaf-containing products) and hepatotoxicity is the leading hypothesis.
For context on how supplement-induced liver damage can escalate, our article on liver transplant in India covers the procedure, costs, and hospital options for severe cases.
Evidence 3: Adulteration Data (584 Samples Tested)
The most damning evidence was the scale of contamination:
| Finding | Number | Percentage |
|---|---|---|
| Total samples tested | 584 | 100% |
| Samples NOT pure root | 119 | 20.4% |
| Samples containing leaf material | 84 | 14.0% |
| Variation in withaferin-A daily intake | — | 70-fold |
One in five products tested was not what the label claimed.
The testing used HPTLC (High-Performance Thin-Layer Chromatography) — a validated analytical technique that can distinguish plant parts based on their chemical fingerprint. Standard withanolide tests used by most manufacturers cannot differentiate root from leaf — both contain withanolides, just in different proportions and compositions.
The American Botanical Council responded by releasing a specific Laboratory Guidance Document for detecting ashwagandha root adulteration — a sign that the problem extends globally, not just in India.
Why Manufacturers Used Leaves
Understanding the economics of adulteration helps you understand which products are at risk.
Leaves Are Cheaper to Produce
| Factor | Roots | Leaves |
|---|---|---|
| Growth time | 150–180 days | Continuous harvest during growth |
| Harvest method | Entire plant uprooted | Leaves picked without destroying plant |
| Processing | Washing, drying, grinding | Simpler — dry and powder |
| Yield per plant | One harvest per lifecycle | Multiple harvests |
| Cost per kg | Higher | Significantly lower |
Mixing leaf material into root powder is economically rational — if you don’t care about consumer safety or honesty.
Detection Was Difficult
Standard quality tests measure total withanolide content. Both roots and leaves contain withanolides. A product adulterated with 50% leaf material could still pass a “withanolide content” test — because the test doesn’t distinguish which plant part the withanolides came from.
Only advanced methods detect the switch:
- HPLC (High-Performance Liquid Chromatography) — separates and identifies specific compounds
- HPTLC — visual fingerprint comparison of chemical profiles
- LC-MS (Liquid Chromatography-Mass Spectrometry) — precise compound identification
- DNA barcoding — genetic verification of plant material
These tests cost ₹5,000–15,000 per sample. Most small manufacturers don’t perform them. Most consumers can’t access them.
Labelling Was Vague
Before the ban, a product could legally say “Ashwagandha 500mg” without specifying root, leaf, or whole plant. This ambiguity was exploited:
- “Ashwagandha powder” — could be anything
- “Whole plant extract” — explicitly includes leaves
- “Ashwagandha extract” — doesn’t specify plant part
- “Root extract” — the only unambiguous safe label
The new labelling requirement closes this gap — manufacturers must now declare the plant part.
Which Products Are Affected
Definitely Unaffected
| Product/Extract | Why |
|---|---|
| KSM-66 | Uses only roots. Proprietary milk-based extraction. Documented supply chain. Root-only policy predates the ban. |
| Products explicitly labelled “root extract” | Already compliant — but verify post-ban labels to confirm continued compliance. |
Potentially Affected (May Need Reformulation)
| Product/Extract | Why |
|---|---|
| Sensoril | Traditionally uses both roots and leaves. Indian products containing Sensoril may need reformulation to exclude leaf-derived material. |
| Shoden | Also uses roots and leaves in its extraction. Same reformulation requirement applies. |
| Products labelled “whole plant” or “whole herb” | Explicitly include leaves — must be reformulated or withdrawn. |
| Generic “ashwagandha powder” without plant part specified | Highest adulteration risk. Must update labels at minimum; may need to change sourcing. |
Brand-Specific Assessment
| Brand | Current Status | Risk Level |
|---|---|---|
| Himalaya Ashvagandha | Labelled as root extract | Low — likely compliant |
| Patanjali Ashwagandha | Labelled as “whole plant powder” (ashwagandha churna) | Needs verification — may need reformulation |
| Organic India | Labelled as organic root | Low — likely compliant |
| Zandu Gold Plus | Extract type undisclosed | Needs verification |
| Kapiva Gold | Extract type undisclosed | Needs verification |
| Nutrabox KSM-66 | KSM-66 root extract | Compliant |
| Carbamide Forte KSM-66 | KSM-66 root extract | Compliant |
For a detailed comparison of all major Indian brands including pricing and potency analysis, see our ashwagandha brand comparison.
The Leaf-Root Paradox: What the Ban Also Removes
Here’s an irony the regulators may not have fully considered.
The active sleep-inducing compound in ashwagandha — triethylene glycol (TEG) — was identified by University of Tsukuba researchers in 2017. They found:
- The withanolide-rich root extract was ineffective at inducing sleep in their study
- The water extract containing TEG (found primarily in leaves) was the active sleep-inducing fraction
- TEG acts through a distinct mechanism from withanolides
The implication: Root-only products — now the only legal option in India — may lack the direct sleep-inducing compound that many consumers take ashwagandha for. Root extracts can still improve sleep indirectly through cortisol reduction and GABAergic modulation, but the primary direct sleep mechanism (TEG) is leaf-based.
This doesn’t make the ban wrong — the hepatotoxicity risk from withaferin-A outweighs the sleep benefit from TEG. But it does mean that consumers taking ashwagandha specifically for sleep may experience reduced efficacy from compliant products.
For evidence-based ashwagandha dosage protocols including sleep-specific recommendations, see our dosage guide.
What Consumers Should Do Now
Step 1: Check Your Current Product
Look at the label of the ashwagandha product you’re currently taking:
Safe indicators:
- States “root extract” or “root powder”
- Uses a named extract: KSM-66
- FSSAI license number present
- Batch number traceable
Red flags:
- Says “whole plant,” “whole herb,” or “plant powder”
- Doesn’t specify which plant part
- No FSSAI number
- Purchased before April 2026 without updated labelling
- Purchased from unregulated source (local shop without branded packaging)
Step 2: Get a Liver Function Test (If Concerned)
If you’ve been taking a product that may have contained leaves, a simple LFT (₹300–500 at most Indian labs) can check for subclinical liver stress:
| Marker | Normal Range | Concern Level |
|---|---|---|
| ALT (SGPT) | 7–56 U/L | >2x upper limit |
| AST (SGOT) | 10–40 U/L | >2x upper limit |
| Total bilirubin | 0.1–1.2 mg/dL | >2.0 mg/dL |
If your values are normal, you’re fine. If elevated, stop ashwagandha and consult a hepatologist. Most cases of ashwagandha liver injury resolve within 1–4 months after discontinuation.
Step 3: Switch to a Verified Root-Only Product
If your current product is questionable, switch to a brand that can verify root-only sourcing:
Highest verification: KSM-66 branded products (Nutrabox, Carbamide Forte) — proprietary supply chain, root-only extraction documented.
Good verification: Himalaya Ashvagandha — established supply chain, WHO-GMP certified, labelled as root extract.
Adequate verification: Organic India — USDA Organic certification includes supply chain audits.
For the complete brand analysis including cost-per-withanolide calculations, see our detailed brand comparison.
Step 4: Report Non-Compliant Products
If you find ashwagandha products containing leaves being sold after April 2026, you can report them:
- FSSAI Consumer Helpline: 1800-112-100
- FSSAI Online Complaint: foscos.fssai.gov.in
- Ministry of Ayush: for traditional medicine products
Global Impact: India’s Ban Affects World Supply
India produces an estimated 80–85% of the world’s ashwagandha supply. The leaf ban has ripple effects:
For Indian Manufacturers
- Must verify and certify root-only sourcing across supply chains
- Audit existing inventory for leaf-containing products
- Update all labels to specify plant part
- Products currently in distribution with non-compliant labelling must be recalled or relabelled
For International Markets
- US, EU, and other markets importing Indian ashwagandha raw material may face supply disruption
- Products using Sensoril or Shoden extracts (root + leaf) sourced from India may need reformulation
- The ban may accelerate adoption of KSM-66 globally as a verified root-only option
- Some countries may follow India’s regulatory lead — India’s evidence base strengthens the case for leaf restrictions elsewhere
For Farmers
- Root-only demand may increase root prices
- Leaf material, previously a revenue source, becomes waste
- Farmer cooperatives may need new buyers for leaf biomass or explore non-supplement applications
- Raw ashwagandha mandi prices: ₹15,000–19,800/quintal as of May 2026 — may increase
The Bigger Picture: Supplement Regulation in India
The ashwagandha leaf ban is part of a broader regulatory tightening in India’s supplement industry.
What FSSAI Has Done Right
- Identified a genuine safety risk — 35 liver injury cases is not a theoretical concern
- Acted on data — the 584-sample study provided concrete evidence of adulteration
- Coordinated with Ayush — both regulators moved in parallel, closing gaps between food and traditional medicine sectors
- Required transparency — mandatory plant part disclosure on labels
What Still Needs to Change
- Mandatory withanolide disclosure — banning leaves addresses one safety issue but doesn’t solve the potency transparency problem. Consumers still can’t compare products on active ingredient content.
- Regular market surveillance — the 584-sample study was a one-time analysis. Ongoing testing of commercial products is needed to verify compliance.
- Penalty enforcement — the Food Safety and Standards Act provides penalties, but enforcement against supplement manufacturers has historically been weak.
- Consumer education — most ashwagandha consumers in India don’t know what withanolides are, why plant part matters, or how to read supplement labels effectively.
The Parallel with Paracetamol Regulation
India’s approach to ashwagandha regulation mirrors its history with paracetamol — a widely consumed substance where regulatory gaps allowed potential harm:
- Paracetamol: The 500mg to 650mg shift exploited a DPCO pricing loophole. Regulation caught up years later.
- Ashwagandha: Leaf adulteration exploited a labelling loophole. Regulation caught up in 2026.
In both cases, consumer safety was compromised by regulatory gaps that manufacturers exploited for economic advantage. And in both cases, the fix came after documented harm — not before.
Timeline of Events
| Date | Event |
|---|---|
| 2017–2025 | 35 case reports of ashwagandha-associated liver injury published globally |
| 2023–2024 | Indian case series documents 8 patients, 3 deaths with pre-existing liver disease |
| 2024–2025 | 584 commercial samples tested — 20.4% found to contain non-root material |
| 2025 | American Botanical Council releases Laboratory Guidance Document for detecting ashwagandha adulteration |
| April 15, 2026 | Ministry of Ayush bans ashwagandha leaves in Ayush drugs and products |
| April 16, 2026 | FSSAI bans ashwagandha leaves in food products, nutraceuticals, and health supplements |
| Post-April 2026 | Manufacturers required to relabel, reformulate, or withdraw non-compliant products |
What This Means for Your Health Decisions
The FSSAI ban is a positive development for consumer safety. But it’s not a complete solution. Even with root-only products:
- Liver injury risk still exists (case reports include root extract users)
- 471 drug interactions remain regardless of plant part
- Thyroid disruption from root extracts increased T3 by 41.5% in trials
- Emotional blunting and withdrawal are reported with root-based products
- Quality variation between brands persists — root extract potency still ranges from 0.5% to 35% withanolides
The ban removes one layer of risk (withaferin-A from leaves) but doesn’t make ashwagandha universally safe. The complete risk profile — including side effects, dosage protocols, and drug interactions — still applies.
For thyroid patients specifically, the interaction between ashwagandha and levothyroxine remains a concern regardless of the leaf ban — root extracts are what the thyroid study used.
The leaf ban protects you from one specific danger. Your own research protects you from the rest.
This article covers FSSAI and Ministry of Ayush regulatory actions as of April 2026. Regulatory status may change — check fssai.gov.in for the latest notifications. This article is for informational purposes and does not constitute legal or medical advice. If you experience symptoms of liver injury (jaundice, dark urine, nausea, abdominal pain) while taking any supplement, stop use and consult a healthcare provider immediately.